Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in Philadelphia-negative chronic myeloproliferative neoplasms
2022-003009-31Phase 2Active
- Sponsor
- Zealand University Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of atorvastatin in thrombocythemia, polycythemia vera (PV) and prefibrotic primary myelofibrosis (pre-PMF), sponsored by Zealand University Hospital. Primary endpoint: Inflammatory markers and cell counts. Started Nov 2022; status: active.
02
Drugs
atorvastatin
03
Conditions
thrombocythemiapolycythemia vera (PV)prefibrotic primary myelofibrosis (pre-PMF)
Beyond the preview
Go deeper on 2022-003009-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003009-31.